Premium
Synthesis of a Ruthenium(II) Compound based on 5‐(2‐Pyrimidyl)‐1H‐tetrazole for Photodynamic Therapy
Author(s) -
Wei Bo,
Guo Meng Yue,
Lu Yi Ming,
Sun Peng Peng,
Yang Gao Wen,
Li Qiao Yun
Publication year - 2018
Publication title -
zeitschrift für anorganische und allgemeine chemie
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.354
H-Index - 66
eISSN - 1521-3749
pISSN - 0044-2313
DOI - 10.1002/zaac.201700343
Subject(s) - ruthenium , phototoxicity , tetrazole , hela , chemistry , photodynamic therapy , reactive oxygen species , irradiation , bipyridine , medicinal chemistry , nuclear chemistry , crystal structure , photochemistry , stereochemistry , crystallography , in vitro , catalysis , organic chemistry , biochemistry , physics , nuclear physics
Ru II compounds have been universally investigated due to their unique physical and chemical properties. In this paper, a new Ru II compound based on 2,2′‐bipy and Hpmtz [2,2′‐bipy = 2,2′‐bipyridine, Hpmtz = 5‐(2‐pyrimidyl)‐1H‐tetrazole], namely [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O was prepared and characterized by elemental analysis, IR and single‐crystal X‐ray diffraction. [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O shows a mononuclear structure and forms a three‐dimensional network by non‐classic hydrogen bonds. The ability of generation of ROS (reactive oxygen species) makes it has a low phototoxicity IC 50 (half‐maximal inhibitory concentration) after Xenon lamp irradiation on Hela cells in vitro. The results demonstrate that [Ru(2,2′‐bipy) 2 (pmtz)][PF 6 ] · 0.5H 2 O with high light toxicity and low dark toxicity may be a potential candidate for photodynamic therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom